Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer
Standard
Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer. / Dulz, Simon; Asselborn, Niels H; Dieckmann, Klaus-Peter; Matthies, Cord; Wagner, Walter; Weidmann, Jens; Seidel, Christoph; Oing, Christoph; Berger, Lars A; Alsdorf, Winfried; Mankichian, Blanche; Meyer, Christian; Vetterlein, Malte W; Gild, Philipp; Ludwig, Tim A; Soave, Armin; Schriefer, Philipp; Becker, Andreas; Ahyai, Sascha A; Oechsle, Karin; Bokemeyer, Carsten; Wagenfeld, Lars; Fisch, Margit; Hartmann, Michael; Chun, Felix K-H; Kluth, Luis A.
In: J CANCER RES CLIN, Vol. 143, No. 7, 07.2017, p. 1319-1325.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer
AU - Dulz, Simon
AU - Asselborn, Niels H
AU - Dieckmann, Klaus-Peter
AU - Matthies, Cord
AU - Wagner, Walter
AU - Weidmann, Jens
AU - Seidel, Christoph
AU - Oing, Christoph
AU - Berger, Lars A
AU - Alsdorf, Winfried
AU - Mankichian, Blanche
AU - Meyer, Christian
AU - Vetterlein, Malte W
AU - Gild, Philipp
AU - Ludwig, Tim A
AU - Soave, Armin
AU - Schriefer, Philipp
AU - Becker, Andreas
AU - Ahyai, Sascha A
AU - Oechsle, Karin
AU - Bokemeyer, Carsten
AU - Wagenfeld, Lars
AU - Fisch, Margit
AU - Hartmann, Michael
AU - Chun, Felix K-H
AU - Kluth, Luis A
PY - 2017/7
Y1 - 2017/7
N2 - PURPOSE: Visual impairment represents an infrequent form of cisplatin-induced neurotoxicity; however, visual deterioration has been reported in several studies. To evaluate potential morphological and functional retinal alterations in patients with germ cell cancer (GCC) treated with cisplatin-based chemotherapy (CBC).METHODS: Multi-disciplinary and multi-institutional study design. Examination of 28 eyes of 14 male GCC patients, who had received at least one cycle of CBC. A matched control group of healthy, untreated patients were included in this study. Subjects underwent a retinal nerve fiber thickness (RNFL) measurement, color vision, visual acuity testing, full-field electroretinograms (ff-ERG). To assess a correlation between cumulative cisplatin dose and measured RNFL and ff-ERG Pearson correlation coefficient analysis was performed.RESULTS: Both study groups (CBC recipients vs. healthy controls) consisted each of 14 participants with a median patient age of 30 years (interquartile range (IQR) 26-37 years). Tumor histology was seminoma in 6 of 14 patients (43%), and non-seminomatous GCC in 8 of 14 patients (57%). Median cumulative cisplatin dosis at examination was 627 mg/m(2) (IQR 413-1013 mg/m(2)). Morphological assessment revealed reduced RNFL in 11 of 14 patients (78.6%). Reduction in RNFL was significantly correlated to the cumulative CBC dose received (rho = + 0.70; p = 0.004). ff-ERG showed significant differences between CBC recipients and the control group in 2 of 5 tested categories (all p values <0.001).CONCLUSION: This study represents first evidence of chronic subclinical retinal toxicity due to cisplatin-based chemotherapy in patients with GCC. The reduction of RNFL might become clinically relevant in upcoming age-related chronic degenerative disorders such as glaucoma.
AB - PURPOSE: Visual impairment represents an infrequent form of cisplatin-induced neurotoxicity; however, visual deterioration has been reported in several studies. To evaluate potential morphological and functional retinal alterations in patients with germ cell cancer (GCC) treated with cisplatin-based chemotherapy (CBC).METHODS: Multi-disciplinary and multi-institutional study design. Examination of 28 eyes of 14 male GCC patients, who had received at least one cycle of CBC. A matched control group of healthy, untreated patients were included in this study. Subjects underwent a retinal nerve fiber thickness (RNFL) measurement, color vision, visual acuity testing, full-field electroretinograms (ff-ERG). To assess a correlation between cumulative cisplatin dose and measured RNFL and ff-ERG Pearson correlation coefficient analysis was performed.RESULTS: Both study groups (CBC recipients vs. healthy controls) consisted each of 14 participants with a median patient age of 30 years (interquartile range (IQR) 26-37 years). Tumor histology was seminoma in 6 of 14 patients (43%), and non-seminomatous GCC in 8 of 14 patients (57%). Median cumulative cisplatin dosis at examination was 627 mg/m(2) (IQR 413-1013 mg/m(2)). Morphological assessment revealed reduced RNFL in 11 of 14 patients (78.6%). Reduction in RNFL was significantly correlated to the cumulative CBC dose received (rho = + 0.70; p = 0.004). ff-ERG showed significant differences between CBC recipients and the control group in 2 of 5 tested categories (all p values <0.001).CONCLUSION: This study represents first evidence of chronic subclinical retinal toxicity due to cisplatin-based chemotherapy in patients with GCC. The reduction of RNFL might become clinically relevant in upcoming age-related chronic degenerative disorders such as glaucoma.
KW - Journal Article
U2 - 10.1007/s00432-017-2384-8
DO - 10.1007/s00432-017-2384-8
M3 - SCORING: Journal article
C2 - 28281024
VL - 143
SP - 1319
EP - 1325
JO - J CANCER RES CLIN
JF - J CANCER RES CLIN
SN - 0171-5216
IS - 7
ER -